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Abstract
In contrast to resource-rich countries, most HIV-infected patients in resource-limited countries receive treatment without
virological monitoring. There are few long-term data, in this setting, on rates of viral suppression or switch to second-line
antiretroviral therapy. The DART trial compared clinically driven monitoring (CDM) versus routine laboratory (CD4/
haematology/biochemistry) and clinical monitoring (LCM) in HIV-infected adults initiating therapy. There was no virological
monitoring in either study group during follow-up, but viral load was measured in Ugandan participants at trial closure. Two
thousand three hundred and seventeen (2317) participants from this country initiated antiretroviral therapy with
zidovudine/lamivudine plus tenofovir (n = 1717), abacavir (n = 300), or nevirapine (n = 300). Of 1896 (81.8%) participants who
were alive and in follow-up at trial closure (median 5.1 years after therapy initiation), 1507 (79.5%) were on first-line and 389
(20.5%) on second-line antiretroviral therapy. The overall switch rate after the first year was 5.6 per 100 person-years; the
rate was substantially higher in participants with low baseline CD4 counts (,50 cells/mm3). Among 1207 (80.1%) first-line
participants with viral load measured, HIV RNA was ,400 copies/ml in 963 (79.8%), 400–999 copies/ml in 37 (3.1%), 1,000–
9,999 copies/ml in 110 (9.1%), and $10,000 copies/ml in 97 (8.0%). The proportion with HIV RNA ,400 copies/ml was
slightly lower (difference 7.1%, 95% CI 2.5 to 11.5%) in CDM (76.3%) than in LCM (83.4%). Among 252 (64.8%) second-line
participants with viral load measured (median 2.3 years after switch), HIV RNA was ,400 copies/ml in 226 (89.7%), with no
difference between monitoring strategies. Low switch rates and high, sustained levels of viral suppression are achievable
without viral load or CD4 count monitoring in the context of high-quality clinical care.
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Introduction
Most resource-limited countries have adopted a public health
approach to anti-retroviral therapy (ART) for the treatment of
HIV infection in which the public sector provides a single first-line
regimen, with alternative substitute drugs as required, and a
standard second-line therapy for those who fail first-line [1,2]. The
limited availability of laboratory tests requires the flexible use of
routine viral load or CD4 count monitoring to detect treatment
failure according to local circumstances [3]. In contrast, the care of
HIV-infected patients in resource-rich countries is highly individ-
ualised, including the regular measurement of viral load to check
that current ART is successfully inhibiting viral replication.
When viral load is not routinely monitored some patients may
experience periods of prolonged undetected viraemia, which has
several potential negative consequences. First, long delays in
switching therapy may place the patient at increased risk of
opportunistic infections although regular CD4 monitoring should
mitigate against this [4]. Second, evidence has emerged that
viraemia per se may have adverse chronic effects, possibly via
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elevated immune activation [5,6]. Third, extensive drug resistance
may develop, thereby compromising the virological efficacy of
second-line ART if there is cross-resistance between drugs used in
first-line and second-line regimens. This also carries a public
health threat in that the transmission of resistant viruses could
increase and thus eventually limit the effectiveness of first-line
ART [7]. Fourth, CD4 count is generally weakly predictive of
virological failure [8], although the association is stronger among
patients with clinical symptoms [9]. Finally, it has been suggested
that patients’ knowledge of their viral load values might help
improve adherence to therapy, although randomised evidence is
lacking [10]. Based on these considerations, several experts have
questioned whether it is ethical to administer ART without viral
load monitoring [4,11–14].
However, these concerns clearly need to be balanced against the
critical point that in any financially-constrained healthcare system
facing static or diminishing funds for HIV/AIDS programmes,
resources directed towards laboratory testing mean that fewer
patients in need of treatment are able to receive it [2,15,16].
Further, routine viral load monitoring results in higher switch rates
to more costly second-line ART [17,18]. Finally, viral load testing
is technically complex, making its application in resource-limited
settings challenging [19]. Some programmes have found that
erroneous results were frequently reported to clinicians, potentially
leading to unnecessary ART regimen change or enhanced
adherence counselling, and undetected virological failure [19].
The debate on viral load monitoring in resource-limited settings
has been conducted with remarkably few relevant data to inform
it. Here we report cross-sectional viral load results after five years
on ART among Ugandan patients in the DART trial, where
clinical management (in particular, switch from first-line to
second-line ART) was based on clinical symptoms with or without
access to CD4 counts in the absence of real-time viral load
monitoring [20].
Methods
Study Overview
DART (Development of Antiretroviral Therapy in Africa) was
an open randomised trial in ART-naive, symptomatic HIV-
infected adults with a CD4 count #200 cells/mm3, enrolled from
three clinical centres in Uganda and one in Zimbabwe between
January 2003 and October 2004 [20]. Participants were
randomised to clinically-driven monitoring (CDM) or routine
laboratory (CD4 cells counts, haematology, and biochemistry tests)
plus clinical monitoring (LCM), and followed under these
strategies until the end of 2008. DART included two sub-studies
of second-line therapy that are pertinent to the current analysis,
both of which opened for recruitment in July 2007 and whose
populations partly overlapped: OHFS (Optimal HAART Feasi-
bility Study) [21] and SARA (Second-line Antiretroviral Therapy
in Africa) [22].
Viral load measurements
Although there was no real-time viral load monitoring in
DART, Ugandan participants were eligible for a viral load test
under the national programme shortly after trial closure.
However, participants who were enrolled in either OHFS or
SARA were ineligible since viral load was measured (retrospec-
tively) at specific time points as part of the protocol of these sub-
studies. To increase the number of available measurements and to
decrease potential bias, we included viral load results from these
two sub-studies that coincided with the testing done within the
national programme (January 2009 to April 2009). All viral load
assays were done in two centres: Joint Clinical Research Centre,
Kampala (Roche Taqman 1.0, lower limit of detection [LLD]= 40
copies/ml) and the Infectious Diseases Institute, Mulago (Roche
Amplicor 1.5, LLD=400 copies/ml). Viral suppression was
defined as HIV RNA,400 copies/ml (i.e. the higher of the two
LLDs).
Antiretroviral regimens
First-line ART regimens comprised co-formulated zidovudine
(ZDV)-lamivudine (3TC) plus either tenofovir (TDF), abacavir
(ABC), or nevirapine (NVP) [20,23]. Following World Health
Organization (WHO) guidelines, the protocol discouraged switch-
ing in the first year of therapy. Thereafter, the decision to switch to
second-line ART was based on clinical criteria (new/recurrent
WHO stage 4 event, WHO stage 3 events at the discretion of the
treating physician) in both groups, along with confirmed CD4
count ,100 cells/mm3 in the LCM group only [20].
All second-line ART regimens included the boosted protease
inhibitor (PI), lopinavir/ritonavir (LPV/r). The nucleoside/nucle-
otide reverse transcriptase inhibitors (NRTIs) and/or non-nucle-
oside reverse transcriptase inhibitors (NNRTI) prescribed in
combination with LPV/r were allocated according to the OFHS
randomisation schedule if the individual participated in this sub-
study, or otherwise at the discretion of the patient’s clinician [21].
In the SARA sub-study, participants who had been on second-line
ART for 24 weeks were randomised between continuing their
boosted PI-containing regimen or reducing to maintenance
boosted PI monotherapy [22].
Statistical methods
The probability of switching to second-line ART by trial closure
was examined by multivariate logistic regression analysis, includ-
ing a priori selected baseline predictors (i.e. monitoring strategy,
age, sex, baseline CD4 count, first-line ART regimen). A simplified
version of this model, combining the two triple NRTI regimens
(ZDV/3TC/TDF, ZDV/3TC/ABC) and excluding non-signifi-
cant covariates (P.0.05), was used to estimate absolute probabil-
ities (by converting from odds) of switching for combinations of
variables. Logistic regression analysis was used to examine if the
absence of a viral load measurement was related to any of the
baseline variables or last available CD4 count. Logistic regression
analysis, applied separately to participants on first-line and second-
line ART, was similarly used to examine predictors of viral
suppression at trial closure, adjusting for duration of the specific
line of ART. Estimates of the overall prevalence of viral
suppression (i.e. combining first-line and second-line regimens)
were derived using weighted averages to account for the relative
under-representation of participants on second-line ART. All
analyses were performed using STATA (version 12.0).
Ethics statement
The study was approved by the Uganda Virus Research
Institute, Entebbe.
Results
A total of 2317 Ugandan patients were randomised in DART,
of whom 275 died (136 within 12 months of trial entry/ART
initiation) and 146 were lost to follow-up before the trial closed
(Figure 1). The following analyses are based on the remaining
1896 (81.8%) patients, whose characteristics at trial entry are
shown in Table 1. Median (IQR, range) follow-up at trial closure
was 5.1 (4.7–5.4, 4.2–6.0) years.
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Switch to second-line ART
The switch rate to second-line ART was low (5.6 per 100
person-years after the first year) and by trial closure only 389
(20.5%, 95% CI 18.7–22.4%) patients had switched to second-line
therapy (Figure 1). From multivariate analysis, significant inde-
pendent baseline predictors of a higher rate of switch to second-
line were randomisation to LCM, male sex, lower baseline CD4
count, and a triple NRTI first-line regimen (Table 1). The effect of
baseline CD4 count (regardless of monitoring strategy) was
particularly strong, showing a clear gradient with the odds of
switching to second-line ART over seven-fold higher in the lowest
CD4 group (,50 cells/mm3) compared with the highest group
(150–199 cells/mm3).
The predicted probability of switching to second-line ART by
five years was calculated for all combinations of significant baseline
predictors; estimates are shown separately by initial ART regimen
(triple NRTI or NNRTI-based) (Figure 2a and 2b). Apart from
patients who initiated ART with ,50 CD4 cells/mm3, these
probabilities were remarkably low, with a minimum value of 3.1%
(NNRTI-based ART, CDM, female, 150–199 CD4 cells/mm3).
Viral load at trial closure
The source and number of viral load measurements are shown
in Figure 1. A viral load measurement was more frequently
available in the Kampala sites (86.3%) than in Entebbe (65.2%)
(P,0.001) but was not otherwise associated with any baseline
patient characteristic (those listed in Table 1) or with last available
CD4 count (result not shown).
Figure 1. Flow diagram of participants and availability of viral
load measurements.
doi:10.1371/journal.pone.0090772.g001
Table 1. Predictors of switch to second-line ART.
Factor Number
Switched to second-line ART, n
(%) Unadjusted OR Adjusted OR (95% CI)1
All patients 1896 389 (20.5) - -
Monitoring strategy P= 0.02
CDM 939 173 (18.4) 1.00 1.00
LCM 957 216 (22.6) 1.29 1.33 (1.04–1.68)
Age at entry (years) P= 0.36
,30 310 76 (24.5) 1.00 1.00
30–34 458 100 (21.8) 0.86 0.86 (0.59–1.23)
35–39 486 84 (17.3) 0.64 0.68 (0.47–0.99)
40–44 340 73 (21.5) 0.84 0.88 (0.59–1.31)
$45 302 56 (18.5) 0.70 0.79 (0.52–1.21)
Sex P,0.001
Female 1294 229 (17.7) 1.00 1.00
Male 602 160 (26.6) 1.68 1.55 (1.21–1.99)
Baseline CD4 (cells/mm3) P,0.001
,50 621 228 (36.7) 7.77 7.38 (4.83–11.28)
50–99 430 82 (19.1) 3.16 2.90 (1.83–4.58)
100–149 442 51 (11.5) 1.75 1.70 (1.04–2.76)
150–199 403 28 (6.9) 1.00 1.00
Initial ART regimen P= 0.013
ZDV/3TC/TDF 1404 315 (22.4) 1.00 1.00
ZDV/3TC/ABC 244 47 (19.3) 0.83 1.29 (0.82–2.03)
ZDV/3TC/NVP 248 27 (10.9) 0.29 0.58 (0.35–0.97)
Duration of follow-up2 - - 1.03 1.03 (1.00–1.06)
Switches observed over median follow-up of 5.1 years.
1. Multivariate logistic regression analysis, adjusting for all factors listed in Table and study site.
2. Per month.
P-value based on test for heterogeneity or test for trend, as appropriate.
doi:10.1371/journal.pone.0090772.t001
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Patients on first-line ART
A viral load measurement at trial closure was available on 1207
(80.1%) patients on first-line ART. HIV RNA was ,400 copies/
ml in 963 (79.8%) patients, 400–999 copies/ml in 37 (3.1%),
1,000–9,999 copies/ml in 110 (9.1%), and $10,000 copies/ml in
97 (8.0%). The frequency of viral suppression (HIV RNA,400
copies/ml) was slightly lower in CDM (76.3%) than in LCM
(83.4%), a difference of 7.1% (95% CI 2.5–11.5%). This was
accompanied by a shift towards a higher proportion of patients
with HIV RNA $10,000 copies/ml in CDM (10.4% versus 5.6%;
difference 4.8%, 95% CI 1.7–7.8%) (Figure 3). Multivariate
analysis confirmed the independent effect of monitoring strategy,
and better virological outcomes among older patients and among
patients who initiated ART with ZDV/3TC/NVP (90.9%
suppressed), with little difference between ZDV/3TC/TDF
(77.7%) and ZDV/3TC/ABC (78.6%) (Table 2). Borderline
significant effects were observed for sex (less suppression among
males) and baseline CD4 count (less suppression at lower values).
The median HIV RNA level among viraemic (HIV RNA $400
copies/ml) patients was 6,310 (IQR 2,040–38,020) copies/ml; the
level of viraemia was not associated (P.0.15) with any baseline
factor.
Patients on second-line ART
A viral load measurement at trial closure was available on 252
(64.8%) patients on second-line ART, at a median (IQR, range) of
2.3 (1.6–3.0, 0.2–4.8) years after switching. HIV RNA suppression
was even higher than among patients on first-line ART: ,400
copies/ml in 226 (89.7%) patients, 400–999 copies/ml in seven
(2.8%), 1,000–9,999 copies/ml in 11 (4.4%), and $10,000 copies/
ml in eight (3.2%) (Figure 3). The distribution of HIV RNA was
almost identical for the two monitoring strategies. No clear
associations with baseline factors were detected, although the
power of this analysis is limited by the small number (26) of
viraemic patients (Table 2). Specifically, there was no evidence of
an effect of duration of second-line ART (P=0.83).
Both lines of ART
Combining results on patients on first-line and second-line
ART, an estimated 81.8% (95% CI 79.8–83.7%) of patients were
virologically suppressed (Table 2). Stratifying by monitoring
strategy, the respective values were 78.8% for CDM and 84.8%
for LCM. For this and other factors, the rate of viral suppression
mainly reflected the patterns observed for patients on first-line
ART, the larger of the two groups.
Discussion
In this cross-sectional analysis of patients who did not receive
real-time viral load monitoring, an estimated 82% had HIV
RNA,400 copies/ml at an average of five years after ART
initiation. An impressive 79% of patients were still on first-line
ART at trial closure – thus, the high prevalence of viral
suppression was not explained by frequent switching to second-
line ART, which included a highly potent boosted PI. These
findings are an important contribution to the debate on laboratory
monitoring strategies in resource-limited settings.
Effect of first-line ART regimen and baseline CD4 count
We identified several factors associated with the rate of
switching to second-line ART and/or the prevalence of viral
suppression among patients who remained on first-line ART. The
factors with the strongest effects were monitoring strategy, ART
regimen, and baseline CD4 count.
LCM was associated with a significantly higher rate of switch to
second-line therapy as a change in regimen could be triggered by a
clinical event or a low CD4 count compared with clinical events
only in the CDM group. Consequently, among participants on
first-line ART, episodes of viraemia are likely to have been more
prolonged in CDM, as evidenced by a lower prevalence of viral
suppression at trial closure in this group.
A distinctive feature of DART was the use of first-line triple
NRTI regimens (received by 87% of patients in the present
analysis). The outcomes for the two NRTI regimens, ZDV/3TC/
TDF and ZDV/3TC/ABC, were broadly similar. However, this is
not a randomised comparison, and the large change in the odds
ratio (from 0.83 to 1.29) in the multivariate analysis of switch to
Figure 2. Estimated probability of switching to second-line ART
by baseline CD4 count and sex. Legend: Probability of switching by
5 years. A) triple NRTI regimens (B) ZDV/3TC/NVP. Black bars denote
LCM group; grey bars denote CDM group.
doi:10.1371/journal.pone.0090772.g002
Figure 3. HIV RNA at trial closure by monitoring strategy and
line of regimen.
doi:10.1371/journal.pone.0090772.g003
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second-line ART is suggestive of confounding, underling the need
for cautious interpretation. The findings on patients who initiated
ART with ZDV/3TC/NVP are likely to be of most interest as this
has been one of the most frequently used drug combinations
worldwide. Patients on this regimen had a significantly lower
switch rate to second-line ART and, consistent with week 48 data,
better virological outcomes [23]. Following the use of first-line
triple NRTI regimen, the OFHS sub-study data suggest that it
may not matter which, if any, NRTIs are included in a second-line
regimen comprising a boosted PI and an NNRTI [21]. While
numbers were small, excellent viral suppression was also observed
in patients who received ZDV/3TC/NVP first-line and thus
received only one new class (boosted PI) in second-line.
The effect of baseline CD4 count on the durability of first-line
ART was remarkably strong, and up to 97% of patients with a
value between 150–199 cells/mm3 remained on their first-line
regimen at the end of follow-up (Figure 2). The much higher
switch rate among participants with a baseline CD4 count less
than 50 cells/mm3 is a further spur to enter patients early into
treatment programmes, before significant immunosuppression has
developed. Also, if DART had been conducted in a less clinically
advanced population (median CD4 count at ART initiation was
86 cells/mm3), it is likely that the overall proportion of patients
who switched to second-line ART would have been substantially
lower.
Comparison with other studies
Most information on viral load outcomes in resource-limited
settings have been reported from treatment programmes that
utilised real-time viral load monitoring. In a large meta-analysis
(.25,000 patients), McMahon and colleagues estimated a pooled
prevalence of viral suppression of 84% (,300–500 copies/ml, on-
treatment analysis) after one year of ART [24]. In a similar
analysis of treatment programmes in Africa, Barth and colleagues
estimated that 76% and 67% patients on first-line ART were
virally suppressed at one and two years respectively, and noted the
scarcity of information beyond this time point [26]. The
comparatively high prevalence of viral suppression among DART
patients on first-line ART (80%) is remarkable for several reasons.
First, the estimate pertains to a much later time point (five years);
second, the identification of virological failure in real-time in other
studies should have prompted more rapid switching to second-line
Table 2. Probability of viral suppression (HIV RNA,400 copies/ml) at trial closure.
First-line ART Second-line ART Both lines of ART
n/N(%)
Adjusted OR (95%
CI)1 n/N(%)
Adjusted OR (95%
CI)1 Probability(%) (95% CI)
All patients 963/1207 (79.8) - 226/252 (89.7) - 81.8 (79.8–83.7)
Monitoring strategy P= 0.003 P = 0.97
CDM 471/617 (76.3) 1.00 94/105 (89.5) 1.00 78.8 (75.7–81.6)
LCM 492/590 (83.4) 1.55 (1.16–2.07) 132/147 (89.8) 0.98 (0.40–2.39) 84.8 (82.1–87.2)
Age at entry (years) P,0.001 P = 0.08
,30 130/182 (71.4) 1.00 39/46 (84.8) 1.00 74.7 (68.7–79.9)
30–34 209/270 (77.4) 1.48 (0.95–2.31) 47/57 (82.5) 0.94 (0.30–2.95 78.5 (73.7–82.6)
35–39 266/326 (81.6) 1.87 (1.20–2.91) 57/60 (95.0) 4.26 (0.95–19.0) 83.9 (80.0–87.2)
40–44 185/225 (82.2) 2.00 (1.23–3.25) 50/53 (94.3) 3.46 (0.72–16.6) 84.8 (80.2–88.5)
$45 173/204 (84.8) 2.40 (1.43–4.03) 33/36 (91.7) 1.86 (0.41–8.40) 86.1 (81.1–89.9)
Sex P= 0.12 P = 0.29
Female 688/850 (80.9) 1.00 122/141 (86.5) 1.00 81.9 (79.4–84.2)
Male 275/357 (77.0) 0.78 (0.57–1.06) 104/111 (93.7) 1.71 (0.63–4.59) 81.5 (77.8–84.6)
Baseline CD4 (cells/mm3) P= 0.05 P = 0.27
,50 240/318 (75.5) 0.64 (0.42–0.97) 136/148 (91.9) 1.84 (0.29–11.7) 81.5 (77.8–84.7)
50–99 233/292 (79.8) 0.77 (0.50–1.19) 51/58 (87.9) 0.87 (0.13–5.97) 81.4 (76.9–85.1)
100–149 240/301 (79.7) 0.75 (0.49–1.15) 26/31 (83.9) 1.10 (0.15–7.91) 80.2 (75.6–84.2)
150–199 250/296 (84.4) 1.00 13/15 (86.7) 1.00 84.6 (80.1–88.2)
Initial ART regimen P= 0.001 P = 0.26
ZDV/3TC/TDF 678/872 (77.7) 1.00 188/207 (90.8) 1.00 80.7 (78.3–82.9)
ZDV/3TC/ABC 125/159 (78.6) 0.90 (0.52–1.53) 21/27 (77.8) 0.40 (0.12–1.32) 78.4 (71.8–83.9)
ZDV/3TC/NVP 160/176 (90.9) 2.78 (1.48–5.20) 17/18 (94.4) 1.70 (0.19–15.1) 91.3 (86.4–94.5)
Duration of first-line ART2 - 0.99 (0.95–1.03) - - -
Duration second-line ART2 - - - 1.00 (0.97–1.04) -
First-line and second-line ART columns show the absolute number (and denominator) of patients with viral suppression (HIV RNA,400 copies/ml). Estimates for both
lines of ART are weighted averages accounting for variation in data completeness (see Methods).
Baseline CD4 refers to CD4 at trial entry.
1. Multivariate logistic regression analysis, adjusting for all factors listed in Table and study site.
2. Per month.
P-value based on test for heterogeneity or test for trend, as appropriate.
doi:10.1371/journal.pone.0090772.t002
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ART; third, the predominant triple NRTI regimens used in
DART compare unfavourably with the more common NNRTI-
based regimens in terms of virological response.
DART also compares favourably with other published studies
that examined response to second-line ART. A recent inclusive
meta-analysis of randomised and observational studies in resource-
limited settings estimated that the cumulative pooled proportion of
patients with virological failure after two years of second-line ART
was 27% (based on five studies) and 38% after three years of
second-line ART (three studies) [25]. However, there was marked
variability between studies, particularly at the three year time
point. In contrast, only 10% of DART patients on second-line
ART had viraemia at trial closure, an average of 2.3 years after
switching. This was despite the fact that 23 (9%) patients were on
sub-optimal boosted PI monotherapy at the time of measurement
[22].
One plausible explanation for the impressive clinical and
virological outcomes in DART is that the clinical care received
by DART participants was generally superior to that received in
routine treatment programmes, enabling high levels of adherence
[26]. That high level care is possible outside the framework of a
clinical trial was demonstrated by an independent study of 998
CD4-monitored patients at one of DART study sites (Infectious
Diseases Institute), which reported 90% patients with HIV
RNA,400 copies/ml after three years of ART, although this site
would have gained experience from participation in a trial [27].
However, individual patients can achieve high levels of adherence
only if drugs are readily and continuously available (as they were in
DART), and there is recognition that drug stock-outs in some
resource-limited settings are a key determinant of treatment failure
[28,29].
Study limitations
Our study has several limitations. First, as discussed above, the
high quality clinical care received by DART participants implies
that the results may not be widely generalizable [26]. A counter
argument is that DART has shown what is achievable, and that
widespread viraemia is not an inevitable consequence of not using
viral load monitoring, as has been predicted [11,12]. Second,
patients who died or were lost to follow-up before study closure
were excluded by definition. However, these represent only 12%
and 6% respectively of the patients enrolled, and the high
proportion (49%) of deaths which occurred within one year of
ART initiation are unlikely to be related to virological failure [30].
Third, while 20% and 35% of patients on first-line and second-line
ART respectively lacked a viral load measurement, there was no
evidence of a systematic difference between those with and without
a measurement, although bias due to the impact of the second-line
sub-studies is difficult to exclude. Fourth, as resistance data are not
currently available we cannot determine whether virological
failure was due to the development of viral resistance or to other
factors, such as non-adherence to ART. Finally, our analysis gives
a snapshot at a single time-point on average five years after ART
initiation. Further testing of DART samples to characterise
longitudinal changes in viral load and the evolution of viral
resistance are ongoing.
Clinical and public health implications
In principle, the best evidence on the value of viral load
monitoring should come from randomised trials of monitoring
strategies that included a viral load monitoring arm (compared
with CD4 only or clinical monitoring). Of the three published
studies with such a study design to date, none discerned any effect
of viral load monitoring on clinical outcomes, but the relatively
small study sizes and short follow-up (2–3 years, before most
patients experience viral rebound) limits their relevance to the
debate on the role of viral load monitoring [31–33].
The cost-effectiveness of viral load monitoring has mainly been
studied in several computer simulation models [18,34,35]. These
have produced widely ranging estimates, with determination of
cost-effectiveness depending critically on an individual country’s
willingness-to-pay threshold. A key input parameter in all models
is the rate of virological failure; if this is low then a large number of
viral load tests need to be performed to identify the few patients in
whom a change of ART may be warranted [36,37]. As discussed
above, there is a scarcity of empirical evidence on the rate of
virological failure beyond the first two years of first-line ART on
which to base this parameter. Our analysis suggests that viral
suppression may be more prolonged than has previously been
thought.
New WHO guidelines issued in July 2013 include a number of
important changes to previous guidelines, including a recommen-
dation that viral load is the preferred monitoring approach to
diagnose and confirm ART failure [38]. However, our analysis
shows that excellent virological outcomes, as well as immunolog-
ical and clinical outcomes [20], are possible without routine CD4
and viral load monitoring of patients on ART, provided therapy is
delivered in the context of high-quality clinical care. National
policymakers need to prioritise between the new WHO recom-
mendations and wider ART coverage, considering available
resources and monitoring approaches that can be practicably
implemented, to maximise health gains in the population [39].
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